Dr. Stacey M. Stein, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 107
Licensed in Connecticut since 2010, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NJ license 25MA12494500 -
Hematology & Oncology Physician
CT license 049046 (first issued 2010; inactive)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Yale-New Haven Hospital New Haven, CT
- Robert Wood Johnson University Hospital New Brunswick, NJ
Medical groups
- Rutgers Health-Rwj Scleroderma Program (391 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 107
- Services billed
- 352
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 225 | 63 |
| Established patient office or other outpatient visit, 40-54 minutes | 21 | 18 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | 13 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Sodium Chloride (0.9 % sodium chloride) Other prescribers in New Haven, CT | 48 |
| Lenvima (lenvatinib mesylate) | 41 |
| Humulin R (insulin regular, human) Other prescribers in New Haven, CT | 26 |
| Imatinib Mesylate | 25 |
| Ondansetron Odt (ondansetron) Other prescribers in New Haven, CT | 22 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 20 payments worth $14,472 in total to this clinician.
| Partner Therapeutics, Inc. | $5,966 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $4,070 |
| Boston Scientific Corporation | $2,275 |
| Guerbet LLC | $2,161 |
| Consulting Fee | $9,345 |
|---|---|
| Travel and Lodging | $2,691 |
| Honoraria | $2,000 |
| Food and Beverage | $436 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Partner Therapeutics, Inc. Mar 6, 2025 | Consulting Fee Bizengri · Hematology/Oncology | $3,000 |
| E.r. Squibb & Sons, L.l.c. May 13, 2025 | Consulting Fee | $2,590 |
| Boston Scientific Corporation May 7, 2025 | Consulting Fee Clinical Trial Product · Clinical Trial Product_PI | $2,275 |
| Guerbet LLC May 30, 2025 | Honoraria Lipiodol · HCC Contrast Agent | $2,000 |
| E.r. Squibb & Sons, L.l.c. Dec 8, 2025 | Consulting Fee | $1,480 |
| Partner Therapeutics, Inc. Feb 14, 2025 | Travel and Lodging Bizengri · Hematology/Oncology · travel to New Orleans, LA | $791 |
| Partner Therapeutics, Inc. Feb 13, 2025 | Travel and Lodging Bizengri · Hematology/Oncology · travel to New Orleans, LA | $692 |
| Partner Therapeutics, Inc. Feb 13, 2025 | Travel and Lodging Bizengri · Hematology/Oncology · travel to New Orleans, LA | $656 |
| Partner Therapeutics, Inc. Feb 13, 2025 | Travel and Lodging Bizengri · Hematology/Oncology · travel to New Orleans, LA · in-kind | $467 |
| Partner Therapeutics, Inc. Mar 6, 2025 | Travel and Lodging Bizengri · Hematology/Oncology · travel to New Orleans, LA | $45.46 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Dec 8, 2025 | Consulting Fee | $1,480 |
| Guerbet LLC May 30, 2025 | Honoraria Lipiodol · HCC Contrast Agent | $2,000 |
| E.r. Squibb & Sons, L.l.c. May 13, 2025 | Consulting Fee | $2,590 |
| Boston Scientific Corporation May 7, 2025 | Consulting Fee Clinical Trial Product · Clinical Trial Product_PI | $2,275 |
| Partner Therapeutics, Inc. Mar 6, 2025 | Consulting Fee Bizengri · Hematology/Oncology | $3,000 |
| Partner Therapeutics, Inc. Mar 6, 2025 | Travel and Lodging Bizengri · Hematology/Oncology · travel to New Orleans, LA | $45.46 |
| Partner Therapeutics, Inc. Mar 6, 2025 | Travel and Lodging Bizengri · Hematology/Oncology · travel to New Orleans, LA | $34.77 |
| Partner Therapeutics, Inc. Mar 6, 2025 | Travel and Lodging Bizengri · Hematology/Oncology · travel to New Orleans, LA | $5.07 |
| Partner Therapeutics, Inc. Feb 14, 2025 | Travel and Lodging Bizengri · Hematology/Oncology · travel to New Orleans, LA | $791 |
| Partner Therapeutics, Inc. Feb 13, 2025 | Travel and Lodging Bizengri · Hematology/Oncology · travel to New Orleans, LA | $692 |
| Partner Therapeutics, Inc. Feb 13, 2025 | Travel and Lodging Bizengri · Hematology/Oncology · travel to New Orleans, LA | $656 |
| Partner Therapeutics, Inc. Feb 13, 2025 | Travel and Lodging Bizengri · Hematology/Oncology · travel to New Orleans, LA · in-kind | $467 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $143,855 in research payments for these studies, mostly to the institutions running them.
- Morpheus NeoAdj HCC
Genentech, Inc. - A phase III,randomised,open label,sponsor blinded,multicentre study of rilvegostomig in combination with bevacizumab with or without tremelimumab as first line treatment in patients with advanced hepatocellular carcinoma
AstraZeneca Pharmaceuticals LP - PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC
Genentech, Inc. - Atezolizumab and bevacizumab in combination with TACE for patients with BCLC B HCC
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.